



# Role of ECDC in implementing EU Action Plan on HIV/AIDS

10<sup>th</sup> Think Tank meeting, Brussels, 9-10 April 2008

Zsuzsanna Jakab, Director, ECDC

ecdc.europa.eu

### Role of ECDC in the Founding Regulation

Identify, assess & communicate current & emerging health threats to human health from communicable diseases

- Detection of health threats through surveillance and epidemic intelligence;
- Provide evidence-based scientific opinions/advise;
- Strengthen preparedness and response
- Capacity building through training;
- Health communication.

ECDC role: risk assessment and evidence based scientific advise to support sound decision making






- Approved by ECDC's Management Board in June 2007;
- Analyses the challenges that infectious diseases will pose to Europe in 2007–2013;
- Specifies ECDC's role in helping the European Union and its MS to compile evidence and to promote the right decisions for the prevention and control those diseases;
- Lists 7 targets that ECDC committed to reach by 2013.

**ECDC long-term strategic vision** 



#### Who are ECDC's strategic partners?



# How is ECDC organised?

## **Director Zsuzsanna Jakab**

#### Cabinet/Office of the Director

- Strategic Management
- Governance
- External Relations, Partnership
- Country Relations

Chief Scientist
Johan Giesecke

Internal Auditor
Stefan Sundbom



Surveillance Unit Andrea Ammon

0

R

Z

0

N

A

P

R

O G R

A

M

M

Data Management and General Surveillance

Disease Specific Surveillance

Scientific Advice Unit Johan Giesecke

Microbiol

Microbiology Coordinator

Evidence Base for Prevention and Control

Scientific and Technical Advice Knowledge Services

Future Threats and Determinants

Preparedness and Response Unit Denis Coulombier

Epidemic Intelligence and Emergency Operations Centre

Outbreak, Preparedness and Support

Epidemiological Training

Health
Communication
Unit
Karl Ekdahl

Scientific Communication

Public Communication and Media

Web Services

Administrative Services Unit Jef Maes

Legal and Procurement

Human Resources

Finance and Accounting

**ICT** 

Missions, Meetings and Logistics

Respiratory Tract Infections (Influenza – Tuberculosis)

STI including HIV and Blood-Borne Viruses Vaccine Preventable Diseases


Antimicrobial Resistance and Healthcare-Associated Infections
Food and Water-Borne Diseases and Zoonoses

**Emerging and Vector-Borne Diseases** 

### HIV/AIDS, STI, Viral hepatitis




Rate of newly diagnosed cases of HIV reported in 2006



### New HIV diagnoses 2001-2006

EU & EEA/EFTA countries









- Commission important on-going close relationship;
- **Think Tank**'s leadership role is fully supported to participate and support its work; contribute to monitor the EU action plan;
- NGOs to establish a closer dialogue with Civil Society Forum;
- Member States to keep continuous interactions on all levels;
- WHO to collaborate within MoU joint surveillance of HIV and TB in European region;
- EMCDDA to collaborate re MoU and share data collection on HIV and hepatitis to avoid double reporting.

ECDC added value: to bring epidemiological data to policy-makers: Bremen/Berlin and in epid report





#### **Surveillance**

- Coordination of EU-wide surveillance of HIV/AIDS
- Develop and implement surveillance for STI, hepatitis B and C

#### Modelling

Develop new user-friendly models for national HIV estimates

#### Communication

 Updated information to stakeholders, professionals and large public

Strategy 1.1- Enhance knowledge of health, economic and social impact in EU





#### **Surveillance**

Develop standardised behavioural surveillance

#### **Research priorities**

Identify research priorities

#### **Review HIV in migrants**

- Assess the epidemiological situation
- Access to health care and testing

Strategy 1.2 - To improve the scientific understanding of HIV determinants





#### Monitoring & evaluation

- Develop M&E programme to monitor Dublin Declaration
- Evaluate key interventions
  - Identify barriers to HIV testing;
  - Identify public health benefit of partner notification for STI and HIV – Call to be launched shortly.

#### **Guidance**

- Guidance for the introduction of HPV vaccines in EU (Jan 08)
- Issue guidance for chlamydia control in Member States (June 08)

Strategy 1.3 – To improve evidence based methods and technologies for prevention and control





#### Monitoring & evaluation

 Country visits (2008: Portugal, Bulgaria, Poland + 2 follow-up visits to Estonia and Romania)

#### **EU level collaboration**

- Commission, Think Tank
- World AIDS Day
- Meet stakeholders
- Etc.

Strategy 1.4 - To strengthen programmes for CD prevention and control at the EU level

#### HIV surveillance in Europe

Transition to ECDC and WHO - Europe




- Joint surveillance by ECDC and WHO-Europe as from 2008
- Transition plan covers:
  - Transfer of the databases for HIV and AIDS (case-based reporting, aggregate reporting)
  - HIV prevalence database
  - Coordination group and annual meeting
- Recommendations from Annual meeting 2007:
  - To improve HIV/AIDS surveillance re quality, completeness and standardisation,
  - To promote case-reporting,
  - To add CD4 counts

#### HIV surveillance in Europe

Framework






#### 53 HIV data providers

National correspondents to be confirmed

#### Data sent to ECDC/WHO joint database

Collection and Validation done by ECDC



#### HIV surveillance in Europe

Transition to ECDC and WHO - Europe



#### **Preparation for data collection:**

- Transfer from old format to new TESSy format
- Protocol for data collection & TESSy converter tool available
- Training for HIV data providers organised in March 2008
- TESSy is up and running testing site available
- Data collection for 2007 starts soon

# HIV surveillance a good mode process and the surveillance and good mode process and good mode

- HIV/AIDS surveillance is a good model of one notification system with Member States;
- Good model for our collaboration with WHO;
  - 53 countries together
  - One database
  - One network
  - Joint annual report.
- We are exploring similar approaches to other diseases under EU-wide surveillance.

#### Behavioural surveillance in Europe



- Behavioural surveillance related to HIV and STI as part of second generation surveillance;
- ECDC's study is starting in April 08:
  - To map behavioural surveillance programmes and specific surveys;
  - To develop a set of behavioural key indicators and methods for behavioural surveillance;
  - Carried out by University of Lausanne.
- Focus on the general population and specific groups at high-risk (homo- and bisexual men, sex workers, STI clinic attendees, individuals living with HIV/AIDS, young people, drug users, ethnic minorities).

#### Behavioural surveillance in Europe



- Overall goal: to facilitate the implementation of standardised behavioural surveillance in EU Member States
- Expected results: toolkit with set of key indicators per group (winter 08/09)
- Workshop on behavioural indicators in MSM in Feb 08 meeting report published shortly; discussions included:
  - Type of sexual technique
  - Safe sex practices
  - HIV testing
  - Time frame
  - HIV serostatus (discordant/concordant couples)

#### **Monitoring and Evaluation Programme**



To monitor the Dublin Declaration in EU

4th Q 2007 Request from Commission to construct a

framework to monitor the Dublin Declaration in

the EU 27 + 3 EEA countries

1st Q 2008 1st draft of the monitoring framework developed

2<sup>nd</sup> Q 2008 Collaboration with key partners in developing DD indicators

3<sup>rd</sup> Q 2008 Tender awarded


4th Q 2009 First ECDC follow-up report published

#### **HIV** testing in EU



#### **Background:**

- About 30% of HIV-infected people in the EU are unaware of their infections;
- Missed opportunities to diagnose HIV in the health care setting;
- Knowledge on practices and barriers to HIV testing & counselling in the EU is lacking;
- Need for improved access, offer, uptake and effectiveness of HIV testing in the EU.




#### **HIV** testing in EU



#### From policy to effectiveness:

- ECDC study to map policies and practices and to identify barriers to HIV testing & counselling;
  - Commissioned to University of Ghent
- Expert meeting took place in Stockholm in January 2007 – report available soon;
- Main goal: to provide evidence-based advice for improving access, offer, uptake and effectiveness of HIV testing & counselling in the EU.



#### Conclusions (1)



- HIV remains a major public health problem both in the EU and in neighbouring countries;
- The diversity of the epidemic across Europe requires adapted local response;
- HIV is a global epidemic and the EU response needs to be seen in this context;
- Sustain and strengthen surveillance activities in Europe to inform prevention programmes & plan health care.

#### Conclusions (2)



- Priorities for prevention in the EU:
  - Reducing barriers to HIV testing;
  - Developing innovative prevention approaches for MSM;
  - Providing specific services for migrant communities;
  - Strengthening prevention and care in high-burden countries
- Political commitment is key support when and where we can
- Commission may wish to call upon ECDC to support the development of the new Action Plan for EU.
- My dream is to turn the epidemic around in Europe(EU)!






### Thank you!

Zsuzsanna Jakab Director ECDC

www.ecdc.europa.eu

# New HIV diagnoses 2001-2006 per million pop, EU15 and EEA/EFTA countries






Note: the graphs are on a different scale!

# New HIV diagnoses 2001-2006 per million pop, Member States which have joined EU since 2004






Note: the graphs are on a different scale!

# New HIV diagnoses 2001-2006 per million pop, EU neighbourhood






Note: the graphs are on a different scale!

# Predominant mode of HIV transmission, cases reported in 2006





This paper was produced for a meeting organized by Health & Consumer Protection DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.